These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 22371753)
1. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Nikfar S; Rahimi R; Rezaie A; Abdollahi M Arch Med Sci; 2010 Apr; 6(2):236-44. PubMed ID: 22371753 [TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for multiple sclerosis. He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123 [TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
4. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561 [TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab for multiple sclerosis. Lin M; Zhang J; Zhang Y; Luo J; Shi S Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174 [TBL] [Abstract][Full Text] [Related]
6. Natalizumab for induction of remission in Crohn's disease. Nelson SM; Nguyen TM; McDonald JW; MacDonald JK Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022 [TBL] [Abstract][Full Text] [Related]
7. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
10. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Gordon M; Taylor K; Akobeng AK; Thomas AG Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347 [TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
12. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N; Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis. Rabea EM; Belal MM; Hafez AH; Elbanna AH; Khalifa MA; Nourelden AZ; Mahmoud NH; Zaazouee MS Acta Neurol Belg; 2024 Apr; 124(2):407-417. PubMed ID: 38457005 [TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444 [TBL] [Abstract][Full Text] [Related]
15. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Gjuladin-Hellon T; Gordon M; Iheozor-Ejiofor Z; Akobeng AK Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008414. PubMed ID: 31220875 [TBL] [Abstract][Full Text] [Related]